Compare Gilead Sciences, Inc. (GILD) vs KraneShares CSI China Internet ETF (KWEB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs KraneShares CSI China Internet ETF — how do they compare? Gilead Sciences, Inc. trades at $149.2 (market cap $182.40B), while KraneShares CSI China Internet ETF trades at $24.86 (market cap $4.37B). The key difference: Gilead Sciences, Inc. is far larger — about 41.7× KraneShares CSI China Internet ETF's market cap, and Gilead Sciences, Inc. pays a 2.23% dividend while KraneShares CSI China Internet ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and KraneShares CSI China Internet ETF for 57 Days on average.
| GILD | KWEB | |
|---|---|---|
Market Cap | $182.40B | $4.37B |
Volume | 4,469,821 | 13,393,361 |
Sector | Health | Sector/Thematic |
52-Week High | $155.80 | $41.35 |
52-Week Low | $116.74 | $23.63 |
Typical Hold Time | 111 Days | 57 Days |
Enterprise Value | $205.46B | — |
Dividend Yield | 2.23% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $146.85, up 1.82% today, with a bullish technical signal from moving averages and recent earnings beats in Q4 2025 and Q1 2026. The company reported strong 2025 revenue of $29.44B and net income of $8.51B, though 2026 projections show a net loss. Key developments include a partnership with PAHO to expand HIV prevention drug access in Latin America, supporting long-term growth prospects amid mixed profitability metrics.
The outlook for GILD is cautiously optimistic, driven by analyst consensus favoring a buy rating (65.52%) and a price target of $151.57. Opportunities lie in HIV and oncology pipeline advancements, but risks include negative 2026 profit margins and high debt levels. Investors should weigh strong cash flow from operations against execution risks in a competitive biopharma landscape.
KWEB trades at $24.87, up 2.22% with bearish technical signals from moving averages and neutral oscillators. Recent news highlights institutional position changes and China-focused economic developments. The ETF faces headwinds from U.S.-China trade dynamics and Chinese industrial overcapacity concerns.
The outlook remains cautious due to geopolitical risks and technical weakness. Investment opportunities exist for those bullish on China's internet sector recovery, but risks include trade tensions and economic rebalancing pressures that could impact performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About KraneShares CSI China Internet ETF
KWEB tracks the CSI Overseas China Internet Index, providing exposure to Chinese software and services companies listed in the US and Hong Kong, including giants like Tencent, Alibaba, and Meituan.
Read more on KWEB →
